Navigation Links
Benefits of ADT Against Risk of Heart Ailments

Androgen deprivation therapy may aggravate heart disease in patients over age 65, according to a new study by researchers at Dana-Farber Cancer Institute. //

ADT is one of the most common treatments for prostate cancer.

The study results were based on data from CaPSURE, a national registry of men with prostate cancer. Although the findings need to be confirmed in clinical trials, the study authors state that oncologists should weigh the benefits of androgen deprivation therapy, or ADT, against the risk of heart problems in older prostate cancer patients.

The researchers will present their study at the Prostate Cancer Symposium in Orlando, Fla., 1:30 pm on Saturday, Feb. 24. The symposium is sponsored by the American Society of Clinical Oncology, the American Society for Therapeutic Radiology and Oncology and the Society of Urologic Oncology.

The goal of ADT is to block the level of circulating androgens (male hormones), which can fuel the growth of prostate cancers. "Androgen deprivation therapy is associated with elevated body mass index, increased body fat deposits and diabetes, all of which raise the risk of death from heart diseased," explains the study's lead author, Henry Tsai, MD, a resident physician at Dana-Farber, Brigham and Women's and the Harvard Radiation Oncology Program.

"Although our findings demonstrated that older men receiving this treatment may be at increased risk, even after taking into account other cardiovascular risk factors, a prospective clinical trial would be needed to confirm a cause-and-effect relationship."

Drawing on the CaPSURE database, Tsai and his colleagues compared the number of cardiac-related deaths among 735 men with localized prostate cancer who received ADT and among 2,901 men with the disease whose treatment did not include ADT.

After factoring in other known risks for cardiovascular disease (such as diabetes, hypertension, body mass ind
'"/>




Page: 1 2

Related medicine news :

1. Benefits in fertility procedures
2. Benefits of Vitamin Supplements Unclear
3. Benefits of Eating Whole Grains, Fruits and Vegetables
4. Benefits of Nitric Oxide in the Treatment of Premature Infants
5. Benefits and Risks of Asthma Treatment Questioned
6. Benefits Of The Worlds Most Widely Used Beverage
7. Drug In Asthma inhaler Found To Counteract Benefits
8. The Benefits Of Keyhole Surgery
9. The Benefits Of A Stretch
10. A Reduction In Calories Found To Yield More Benefits
11. The Benefits Of Soy
Post Your Comments:
(Date:7/25/2008)... DALLAS, July 25 /PRNewswire/ -- BeaconEquity.c...tocks making news today., Investors can view all ...http://BeaconEquity.com/m , Today,s Trade Alerts ...),MiddleBrook Pharmaceuticals Inc. (Nasdaq: MBRK...daq: ADLR ), Affymetrix Inc. (Nasdaq: AFFX ) and...
(Date:7/25/2008)... Expanded Relationship Based on Significant Improv...wswire/ -- MDdatacor, Inc., a leader in health,car...d providers, today,announced it has entered into a...ue to support Wellmark,s Collaboration on Quality(... collaboration between Wellmark and,primary care c...
(Date:7/25/2008)... CARLSBAD, Calif., July 25 /PRNewswire/ -- Auto... registration statement on Form S-1 with the,Secur...osed initial public,offering of shares of its comm...be offered, all of which are expected to be offere...he offering, have not yet been,determined., J.P. ...
(Date:7/25/2008)... Whether you are an Olymp...d Warrior, there are Five Things You Need to Know ...the D.I.S.C. Spine and Sports Center , ...25, 2008 -- America,s premier athletes are heading...onditioning and sacrifice in the hopes of capturin...
Breaking Medicine News(10 mins):Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 3Health News:MDdatacor Extends Contract with Wellmark, Inc. 2Health News:MDdatacor Extends Contract with Wellmark, Inc. 3Health News:AutoGenomics, Inc. Files Registration Statement for Initial Public Offering 2Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 2Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 3Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 4Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 5
...nge name for something even more surprising - a cu...ent, and its Vietnamese advocates say it ends depe...ays. This happens without side effects and without... with the Methadone treatment). If it is really a ...
...eveals for the first time one of the mechanisms by... skin cancer, grows and spreads. This discovery ma...ll arsenal of treatments available for this danger...ew melanoma treatment target in decades. Study pro...
... initiated by World HealthOrganization's (WHO) aut...le official and unofficialsources, soon after any ...o international publichealth. In a crucial decisio... WHO would carry out a through on-the-spotinvestig...
...t of elderly people over age 85 have Alzheimer’s d...mone therapy may cause some postmenopausal women t...with many cognitive disorders, including Alzheimer...ty studied more than 4,500 postmenopausal women wh...
Other Medicine News:Health News:Hope for First New Melanoma Treatment in Decades 2
(Date:7/24/2008)...FirstCall/ -- MacroChem Corporation (OTC,Bulletin ...clinical trial,involving 37 patients who completed... and safety study of EcoNail, a topical antifungal...fungus). The composite,primary efficacy endpoint o...e mycology (negative fungal culture and negative K...
(Date:7/23/2008)...-- Sound Pharmaceuticals (SPI) has filed,an Invest...e clinical,testing of a proprietary formulation of...d hearing loss or ototoxicity. The oral capsule,co...nced stage lung cancer,and head and neck cancer pa... marks the second development program for SPI to e...
(Date:7/23/2008)...wire/ -- InCode BioPharmaceutics, Inc.,an emergin...inical test,results demonstrating the utility of t...f the rare chronic blood disorder paroxysmal noctu...ll be presented at the XXII,International Compleme...008., The only treatment currently available for ...
(Date:7/22/2008)... a multi-center 293-patient European, trial -, ...Symbol: CYT, MONTREAL, July 22 /PRNewswire-FirstC...eader in cryotherapy products to treat cardiac,arr...presented from three,European study centers using ...published earlier today in the Journal of the Amer...
Breaking Medicine Technology:MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 2MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 3MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 4MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 5Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer 2InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) 2CryoCath Arctic Front(R) Results Published in JACC 2CryoCath Arctic Front(R) Results Published in JACC 32008 Social Security Report Offers Dire Warning 15317 12008 Social Security Report Offers Dire Warning 15317 2Core Informatics Completes Successful LIMS Implementation for Progenics Pharmaceuticals 4226 1Cells from the Research Institute of the MUHC on the road to China 15315 1Cells from the Research Institute of the MUHC on the road to China 15315 2Yale study shows weight bias is as prevalent as racial discrimination 15312 1
...tudy Results Presented at Society of Nuclear,Medic...RNewswire-FirstCall/ --,Immunomedics, Inc. , a bio...lonal antibodies to treat cancer and other serious...bryonic antigen,(CEA) antibody, labetuzumab, label... be safe and active when given in two doses,to pat...
...IRE)--Jun 4, 2007 - Pfizer announced today that,ax...tive inhibitor,of VEGFR 1, 2,3 (vascular endotheli...gemcitabine showed a trend towards prolonged,overa...tic cancer,compared with gemcitabine alone, accor...I trial., These data were presented at the 43rd Am...
Other Medicine Technology:Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases 2Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases 3Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases 4Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases 5New Data Show Pfizer's Axitinib Prolonged Overall Survival in,Advanced Pancreatic Cancer When Combined with Standard of Care,Chemotherapy 2New Data Show Pfizer's Axitinib Prolonged Overall Survival in,Advanced Pancreatic Cancer When Combined with Standard of Care,Chemotherapy 3New Data Show Pfizer's Axitinib Prolonged Overall Survival in,Advanced Pancreatic Cancer When Combined with Standard of Care,Chemotherapy 4
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
Medicine Products: